Clinical trials: Uncontrolled Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week) administration to Type 1 and Type 2 diabetes patients (non-smokers)
- Trial name
- NCT00527397
- Testing
- CP-464,005
- Where
- 10 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 1
Observational Study With InnoLet® in Daily Clinical Practice
This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492959
- Testing
- insulin human
- Where
- South Korea
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus
This study is conducted in Europe. An observational study evaluating glycaemic control in patients using Levemir® as initiation insulin therapy as the treatment of type 2 diabetes in Slovakia.
- Trial name
- START (NCT00687284)
- Testing
- insulin detemir
- Where
- Slovakia
- Volunteers
- 2,188 people
- Sponsor
- Novo Nordisk A/S
Diabetic Ketoacidosis, Uncontrolled Type 1 Diabetes Mellitus
DKA Optic Ultrasound
Diabetic ketoacidosis (DKA) is a complication of type 1, or "insulin-dependent," diabetes (T1DM) and is defined by a high blood glucose level (over 200 mg/dL) coupled with severe acidosis.
- Trial name
- DKA Optic US (NCT02130180)
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Diabetes Mellitus, Type 1
Assess the Impact of Insulclock on Glycemic Variability and Treatment Compliance in Uncontrolled DM1 Patients
Insulclock® is a small electronic device developed to facilitate the optimal administration of insulin. This device works as an add-on module of commercially available insulin pens and monitors the date, time and dose of…
- Trial name
- Segoclock2 (NCT04847778)
- Testing
- Use of Insulclock system, both Insulclock device and Insulclock 360 app., Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.
- Where
- 4 sites in Spain
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hospital General de Segovia